TPC VS. GP Induced Chemotherapy Combined With Nimotuzumab and Toripalimab in the Treatment of Locally Advanced Nasopharyngeal Carcinoma

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

416

Participants

Timeline

Start Date

August 20, 2024

Primary Completion Date

August 20, 2028

Study Completion Date

August 20, 2031

Conditions
High Risk Locally Advanced Nasopharyngeal Carcinoma
Interventions
DRUG

Nimotuzumab,Toripalimab,Cisplatin, albumin paclitaxel, capecitabine

Albumin paclitaxel 200g/m2, intravenous drip administration, d1; Cisplatin 60 mg/m2, Intravenous , d1; Capecitabine, 1000mg/m2, orally administered D1-14; Triprolizumab injection 240mg, intravenous D1; Nivolumab 400mg, intravenous D1; Q3W 1 cycle, 3 cycles Period, 3 weeks in total

DRUG

Nimotuzumab,Toripalimab,Cisplatin, Gemcitabine

Cisplatin 80 mg/m2, Intravenous drip administration, d1; Gemcitabine, 1000mg/m2,Intravenous ,D1,D8; Triprolizumab injection 240mg, intravenous ; Nivolumab 400mg, intravenous; Q3W 1 cycle, 3 cycles

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT06561763 - TPC VS. GP Induced Chemotherapy Combined With Nimotuzumab and Toripalimab in the Treatment of Locally Advanced Nasopharyngeal Carcinoma | Biotech Hunter | Biotech Hunter